Photo from wikipedia
Sign Up to like & get
recommendations!
1
Published in 2018 at "Cancer treatment reviews"
DOI: 10.1016/j.ctrv.2018.05.014
Abstract: Inhibition of Poly (ADP-ribose) polymerase (PARP) has shown marked benefit for breast cancer with homologous recombination deficiency, whether driven by defects in BRCA1, BRCA2, or other pathway components. Since the initial approval of olaparib, a…
read more here.
Keywords:
benefit;
platinum;
parpi;
breast cancer ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2020 at "Expert Opinion on Emerging Drugs"
DOI: 10.1080/14728214.2020.1773791
Abstract: ABSTRACT Introduction Poly (ADP-ribose) polymerase (PARP) inhibitors have demonstrated significant anticancer activity in cancers harboring homologous recombination deficiency (HRD), exemplified by high grade serous ovarian cancer (HGSC). PARP inhibitors (PARPi) are being used in women…
read more here.
Keywords:
parp inhibitors;
treatment;
parpi;
ovarian cancer ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2019 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noz175.141
Abstract: A subset of human tumors, including all IDH1-mutant astrocytomas, use a homologous recombination-based alternative lengthening of telomere (ALT) pathway to resolve telomeric dysfunction in the absence of TERT. Because ALT is not used by normal…
read more here.
Keywords:
parpi;
alt mechanism;
parp;
alt ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2018 at "ESMO Open"
DOI: 10.1136/esmoopen-2018-eacr25.511
Abstract: Introduction Error-free repair of double-strand DNA breaks is achieved by homologous recombination (HR), and both BRCA1 and BRCA2 are crucial for this process. Inactivating germline mutations of BRCA1 and BRCA2 genes predispose to breast and…
read more here.
Keywords:
functional genetic;
deficient;
parpi;
resistance ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2023 at "International Journal of Gynecological Cancer"
DOI: 10.1136/ijgc-2022-004190
Abstract: The incidence of myeloid neoplasms following treatment with poly (ADP-ribose) polymerase inhibitors (PARPi) in patients with ovarian cancer has been gradually increasing over the last few years. The cumulative exposure to PARPi and the improved…
read more here.
Keywords:
parpi;
ovarian cancer;
myeloid neoplasms;
neoplasms post ... See more keywords
Photo by nci from unsplash
Sign Up to like & get
recommendations!
1
Published in 2022 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2022-005627
Abstract: Background Poly (ADP-ribose) polymerase (PARP) inhibition (PARPi) has demonstrated potent therapeutic efficacy in patients with BRCA-mutant ovarian cancer. However, acquired resistance to PARPi remains a major challenge in the clinic. Methods PARPi-resistant ovarian cancer mouse…
read more here.
Keywords:
parpi;
ovarian cancer;
resistance;
parp inhibition ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2022 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-22-0301
Abstract: Abstract Purpose: We hypothesized that inhibition and trapping of PARP1 alone would be sufficient to achieve antitumor activity. In particular, we aimed to achieve selectivity over PARP2, which has been shown to play a role…
read more here.
Keywords:
parpi;
inhibitor;
generation;
parp1 ... See more keywords
Sign Up to like & get
recommendations!
2
Published in 2023 at "Molecular cancer therapeutics"
DOI: 10.1158/1535-7163.mct-22-0396
Abstract: Therapy-induced senescence (TIS) is common in tumor cells treated with poly (ADP-ribose) polymerase inhibitors (PARPis), and can serve as a promising target for improving PARPi efficacy. However, whether stromal components within the tumor microenvironment undergo…
read more here.
Keywords:
parpi;
ovarian cancer;
senescence;
tumor ... See more keywords
Photo from wikipedia
Sign Up to like & get
recommendations!
3
Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-5610
Abstract: Purpose: Poly(ADP-ribose) polymerase enzyme inhibitors (PARPi) have become the standard-of-care treatment for homologous recombination deficient (HRD) high-grade serous ovarian cancer (HGSOC). However, not all HRD tumors respond to PARPi and biomarkers to predict response are…
read more here.
Keywords:
ftt pet;
response;
cancer;
parpi ... See more keywords
Sign Up to like & get
recommendations!
2
Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-ct018
Abstract: Introduction: ATRi and PARPi combinations kill tumor cells via synergistic modulation of complementary DDR pathways but clinical utility is limited by overlapping toxicities. A genome-wide CRISPR-Cas9 screen identified DDR alterations that sensitize tumors to the…
read more here.
Keywords:
parpi;
atri camonsertib;
solid tumors;
response ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-142069
Abstract: Introduction: Poly (ADP-ribose) polymerase inhibitors (PARPi's) represent a newer class of antineoplastic agents targeting cancers with defective DNA-damage repair. PARPi's indications include subtypes of ovarian, fallopian tube and primary peritoneal cancer as well as subsets…
read more here.
Keywords:
parpi;
aml mds;
mds;
approval ... See more keywords